GeneThera, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, net loss was USD 0.406256 million compared to USD 0.736479 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago.